Results 21 to 30 of about 9,181,201 (335)

Optogenetic neuromodulation with gamma oscillation as a new strategy for Alzheimer disease: a narrative review [PDF]

open access: yesJournal of Yeungnam Medical Science, 2022
The amyloid hypothesis has been considered a major explanation of the pathogenesis of Alzheimer disease. However, failure of phase III clinical trials with anti-amyloid-beta monoclonal antibodies reveals the need for other therapeutic approaches to treat
Haneol Ko, Sang-Pil Yoon
doaj   +1 more source

Donanemab in Early Alzheimer's Disease.

open access: yesNew England Journal of Medicine, 2021
BACKGROUND A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease.
M. Mintun   +12 more
semanticscholar   +1 more source

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET

open access: yesActa Neuropathologica Communications, 2018
This study aimed to determine the pattern of [18F]flortaucipir uptake in individuals affected by Gerstmann-Sträussler-Scheinker disease (GSS) associated with the PRNP F198S mutation.
Shannon L. Risacher   +11 more
doaj   +1 more source

Cognitive Decline Detection for Alzheimer’s Disease Patients Through an Activity of Daily Living (ADL)

open access: yesIEEE Transactions on Neural Systems and Rehabilitation Engineering, 2022
There are conventional screening instruments for the detection of cognitive impairment, but they have a reduced ecological validity and the information they present could be biased.
G. Palacios-Navarro   +3 more
doaj   +1 more source

Alzheimer's disease.

open access: yesCold Spring Harbor Perspectives in Biology, 2011
Over the last three decades, advances in biochemical pathology and human genetics have illuminated one of the most enigmatic subjects in biomedicine--neurodegeneration.
D. Selkoe
semanticscholar   +1 more source

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

open access: yesThe journal of prevention of Alzheimer's disease, 2022
Alzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis.
Samantha Budd Haeberlein   +23 more
semanticscholar   +1 more source

2020 Alzheimer's disease facts and figures

open access: yesAlzheimer's & Dementia, 2020
This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society.

semanticscholar   +1 more source

Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)

open access: yesAlzheimer's & Dementia, 2021
The estimate of people with clinical Alzheimer's disease (AD) and mild cognitive impairment provides an understanding of the disease burden.
K. Rajan   +5 more
semanticscholar   +1 more source

Deciphering the factors that influence participation in studies requiring serial lumbar punctures

open access: yesAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
Introduction Cerebrospinal fluid biomarkers increasingly inform the causes of dementia and may provide objective markers of disease progression. There is a need to decipher participant and procedural factors that promote participation in studies ...
Gregory S. Day   +3 more
doaj   +1 more source

The Road to Recovery: A Pilot Study of Driving Behaviors Following Antibody-Mediated Encephalitis

open access: yesFrontiers in Neurology, 2020
Introduction: Safe driving requires integration of higher-order cognitive and motor functions, which are commonly compromised in patients with antibody-mediated encephalitis (AME) associated with N-methyl-D-aspartate receptors or leucine-rich glioma ...
Gregory S. Day   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy